Most people have never heard of pharmaceutical compounding. But if you’ve been following the surge in GLP-1 weight-loss medications, you’ve almost certainly encountered it — whether you knew it or not.
Real compounding has a legitimate place in medicine: a licensed pharmacist, working from a valid prescription, prepares a customized medication for one patient when the FDA-approved drug is medically inappropriate. Patient-specific, clinician-directed, strictly regulated. That is what compounding is.
What is happening in the GLP-1 market today is not compounding. Multi-billion-dollar companies are churning out untested, non-FDA-approved knockoffs and selling them to as many as 1.5 million Americans. It’s a business model that profits from the trust Americans place in their medicines.
Mass-compounded GLP-1s are widely marketed and distributed, and the patients taking them are often told these products are approved by the FDA, meaning they’ve been tested, verified, and held to the gold standard for safety. But compounded versions haven’t cleared any of those bars. Furthermore, they’re not clinically proven nor equivalent to the approved products they copy.
Americans for Safe and Effective Medicines was purpose-built to fix the status quo. Our focus is straightforward:
- Stop illegal drug manufacturing,
- Bar unverified foreign ingredients from entering American medicines, and
- Hold mass compounders accountable for deceiving patients.
The FDA is taking steps to address these growing concerns and is currently accepting public comments on a proposed rule that would restrict large-scale GLP-1 compounding — but federal action alone will not be enough. Meaningful oversight and enforcement must follow these products across state lines and onto the online platforms where they are marketed, distributed, and dispensed to patients.
American patients deserve American standards. ASEM is here to fight for them.